Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immuron Limited - American Depositary Shares
(NQ:
IMRN
)
0.9050
+0.0750 (+9.04%)
Streaming Delayed Price
Updated: 10:02 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immuron Limited - American Depositary Shares
< Previous
1
2
3
Next >
Immuron New U.S. Department of Defense Award & Clinical Trial Update
December 03, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron IMM-529 IND approved by FDA
November 05, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Clinical Trial Update
October 31, 2025
From
Immuron Limited
Via
GlobeNewswire
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
October 17, 2025
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on...
Via
Newsfile
Immuron Q1 FY26 YoY growth
October 13, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Submits IMM-529 IND to FDA
October 08, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Letter to Shareholders – Projects Update
October 02, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron partners with InvestorHub
August 26, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron - FY25 global sales exceed projection, up 49% on prior year
July 17, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Letter to Shareholders: Projects Update
May 30, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Travelan® highest sales in history
April 10, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
March 05, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Travelan® continued strong sales growth
January 17, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
January 15, 2025
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Travelan® Clinical Trial Update
January 14, 2025
From
Immuron Limited
Via
GlobeNewswire
UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
December 06, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
December 06, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
December 03, 2024
Via
ACCESSWIRE
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
December 03, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
December 02, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
November 21, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
November 18, 2024
Via
ACCESSWIRE
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
October 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Travelan® continued strong sales growth
October 15, 2024
From
Immuron Limited
Via
GlobeNewswire
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
October 04, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
August 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
August 15, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
August 07, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron announces record Travelan® sales globally, Australia and USA
July 15, 2024
From
Immuron Limited
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
